PGP and non-small cell lung carcinoma: β-ELE may be able to overcome drug resistance in human NSCLC A549/ER cells that are resistant to erlotinib (ER) in vitro by lowering P-gp expression, suppressing P-gp dependent drug efflux, and increasing intracellular concentrations of anticancer drugs (Lin et al., 2018).